by Maria Zannes | Sep 23, 2021 | Press Releases
Australian Patent Office Issues Notice of Acceptance for Patent Related to Porphyrin Compounds and Compositions to Treat Cancer SEPTEMBER 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, announced that the Australian Patent Office...
by Maria Zannes | Sep 14, 2021 | Press Releases
CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer...
by Maria Zannes | Aug 12, 2021 | Press Releases
AUGUST 12, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled...
by Maria Zannes | Jun 23, 2021 | Events, Press Releases
JUNE 23, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25,...
by Maria Zannes | Mar 3, 2021 | Press Releases
MARCH 3, 2021 (SAN ANTONIO, TX) Peer-Reviewed Paper Explains How Porphyrins Used in Company’s Diagnostic and Therapeutic Platforms Enter Cancer Cells bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced...
by Maria Zannes | Feb 4, 2021 | Press Releases
FEBRUARY 4, 2021 (SAN ANTONIO, TX) China’s leading healthcare company to evaluate bioAffinity’s non-invasive, highly accurate test for early-stage lung cancer with aim to commercialize in world’s largest market Shanghai Fosun Long March Medical Science Co., Ltd....
